bgne neutral tislelizumab launch china
messag bgne report financi result provid pipelin updat
gener consist previous provid guidanc product sale
higher consensu driven predominantli strong initi tislelizumab launch
china sale report first month market partial off-set
lower sale three legaci product abraxan revlimid vidaza brukinsa earli
launch indic encourag accord bgne although total
sale remain low given approv mcl indict repres modest initi
opp ty drug updat estim reflect result maintain
neutral rate
product sale street consensu driven predominantli
tislelizumab china bgne report financi result includ product
revenu lower previou quarter consensu tislelizumab
inhibitor launch china appear good start total sale
report first month market march bgne acknowledg potenti
channel in-stock typic earli drug launch initi tislelizumab launch
far compar well two domest inhibitor competitor sintilimab innvov
toripalimab junshi bioscenc book
respect first launch quarter first full calendar year
market product revenu three legaci product abraxan revlimid
vidaza qoq due neg impact pandem
increas gener competit suspens abraxan sale china nmpa
march link brukinsa btk inhibitor sale although bgne
note earli launch indic includ new patient start reimburs coverag
physician percept encourag expens
qoq consensu attribut continu increas spend late-
stage pivot clinic trial develop expens associ collabor
prepar addit regulatori submiss manufactur cost relat
pre-commerci activ suppli
pipelin updat by-and-larg consist previous provid guidanc
brukinsa treatment patient hospit infect pulmonari
distress primari complet date juli full result phase
aspen studi waldenstrm macroglobulinemia patient present
upcom virtual meet see note regulatori discuss fda
ema plan cll top-lin result phase sequoia studi
line cll continu guid earli phase alpin studi
r/r cll complet enrol patient previous
potenti approv brukinsa mcl cll snda file wm china
tislelizumab inhibitor consist previou guidanc enrol
phase global studi nsclc esophag squamou cell
carcinoma escc complet follow announc posit top-lin
result squamou non-squam nsclc china phase studi bgne
present result front-lin squamou nsclc studi upcom
virtual meet submit snda china first-lin non-squam nsclc
bgne also plan initi phase trial china patient resect stage ii
iiia nsclc regulatori discuss base global phase ii trial liver
cancer still guid
pamiparib parp inhibitor phase ii studi china patient advanc
neg breast cancer harbor germlin brca mutat complet enrol
page analyst certif import disclosur
regulatori potenti nda submiss base china phase ii studi brca
ovarian cancer patient remain track top-lin result china phase
studi mainten treatment patient recurr ovarian cancer continu
expect accord bgne
earli stage program anti-tigit monoclon antibodi
evalu global phase studi initi result guid earli
phase studi inhibitor initi patient enrol
previous guid evalu monotherapi combin
zanubrutinib patient b-cell malign
collabor program addit data phase studi sitravatinib
tislelizumab present medic meet bgne
initi enrol zyme phase studi first-lin breast cancer
gastroesophag adenocarcinoma gea bgne expect start enrol patient
pivot biliari tract cancer trial registr first-lin
gea studi late earli first patient dose australia
phase trial evalu raf dimer inhibitor mapkur expect
expand side follow submiss ind
model updat increas tislelizumab fy sale estim china
reflect strong launch lower three legaci product fy sale
estim account competit gener product well
impact
page analyst certif import disclosur
valuat risk
neutral bgne valu use dcf base valuat method valuat
includ commerci product bgne acquir celg part collabor
includ abraxan revlimid vidaza well probability-adjust cash flow deriv
drug candid develop zanubrutinib tislelizumab pamiparib
use discount rate consist commerci stage biotech compani
coverag termin growth rate appli termin year post patent expir
compar similar compani coverag
 regulatori commerci setback
potenti emerg new competitor
dilut financ beyond assum
pipelin success beyond alreadi account model
page analyst certif import disclosur
amort intang
total incom expens
net incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
amort intang
total incom expens
net incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
